Spectrum of natural antibodies against five HTLV-III antigens in infected individuals: correlation of antibody prevalence with clinical status.
Spectrum of natural antibodies against five HTLV-III antigens in infected individuals: correlation of antibody prevalence with clinical status.
复制标题
感染个体中针对五种 HTLV-III 抗原的天然抗体谱：抗体流行率与临床状态的相关性。
作者：
G. Franchini;M. Robert;A. Aldovini;N. Kan;F. Wong
HTLV-III/LAV逆转录病毒是获得性免疫缺陷综合征（AIDS）的病原，其基因组编码病毒结构蛋白（包膜和核心蛋白）、逆转录酶、一种反活化蛋白（tat-III）以及另外两种功能未知的蛋白（3'orf, sor）。我们研究了HTLV-III感染个体血清中抗envelope、gag、3'orf、sor和tat-III的天然抗体的患病率，试图将临床状态与特定HTLV-III抗原的血清阳性联系起来。我们选择了101种血清；16例来自无已知危险因素的正常献血者，85例来自完全艾滋病患者（28例）、艾滋病相关复合物（ARC， 22例）和健康高危人群（同性恋者、静脉吸毒者、艾滋病患者亲属，35例）。采用破坏HTLV-III病毒体的Western blot检测抗包膜（gp41）和gag抗原（p15, p24）抗体的血清阳性。在101份血清中，所有16份来自无风险供者，3/35份来自健康的有风险供者，针对gp41或p15和p24的抗体均为阴性。其余82份血清gp41和/或p15和p24均呈血清阳性。然后对所有血清进行三种已知HTLV-III抗原（3'orf， sor和tat-III）的检测，这些抗原已在细菌中合成。我们的数据表明，所有HTLV-III抗原在体内都具有免疫原性。针对gp41的抗体流行率（接近100%）和针对3'orf、sor和tat-III蛋白的抗体流行率（约50%）在疾病分期方面没有观察到显著差异。相比之下，针对核心抗原的抗体的流行率从无临床疾病症状的感染者的大约100%下降到ARC和艾滋病患者的50%。在艾滋病组中，所有五种抗原血清检测呈阳性的患者比例有所增加。这些结果表明，使用病毒包膜抗原获得的抗体患病率最高，并进一步表明，用新发现的3'orf， sor和tat-III蛋白作为抗原进行筛选不会获得进一步的诊断优势。在疾病进展过程中观察到的天然抗体模式未提示任何发病机制。
The genome of the HTLV-III/LAV retrovirus, the etiologic agent of the acquired immunodeficiency syndrome (AIDS), encodes the viral structural proteins (envelope and core proteins), the reverse transcriptase, a transactivation protein (tat-III), as well as two other proteins (3'orf, sor) of unknown function. We studied the prevalence of natural antibodies against envelope, gag, 3'orf, sor, and tat-III in the sera of HTLV-III infected individuals in an attempt to correlate clinical status with seropositivity to specific HTLV-III antigens. We selected 101 sera; 16 were obtained from normal donors with no known risk factors, and 85 were from patients with full-fledged AIDS (28 cases), AIDS-related complex (ARC, 22 cases), and healthy people at risk (homosexuals, intravenous [IV] drug users, relatives of AIDS patients; 35 cases). Seropositivity for antibodies against the envelope (gp41) and gag antigens (p15, p24) was determined by Western blot using disrupted HTLV-III virions. Of the 101 sera, all 16 from nonrisk donors and 3/35 from healthy at-risk donors were negative for antibodies against either the gp41 or p15 and p24. The remaining 82 sera were seropositive for either the gp41 and/or the p15 and p24. All sera were then tested against the three known HTLV-III antigens (3'orf, sor, and tat-III) that have been synthesized in bacteria. Our data indicate that all the HTLV-III antigens tested are immunogenic in vivo. No significant difference in antibody prevalence to gp41 (close to 100%) and to the 3'orf, sor, and tat-III proteins (approximately 50%) was observed with regard to stage of the disease. In contrast, the prevalence of antibodies against the core antigens decreased from approximately 100% in infected people with no clinical signs of disease to 50% in ARC and AIDS patients. The percentage of patients seropositive for all five antigens tested was increased in the AIDS group. These results indicate that the greatest antibody prevalence was obtained using viral envelope antigen and further suggest that screening with the newly identified 3'orf, sor, and tat-III proteins as antigens would confer no further diagnostic advantage. The pattern of natural antibodies observed during disease progression did not suggest any pathogenetic mechanism.
影响因子：
56.9
作者：
ALLAN, JS;COLIGAN, JE;ESSEX, M
通讯作者：
ESSEX, M
人类 T 细胞嗜淋巴细胞病毒 III 型基因组上反式激活区的位置。
DOI：
10.1126/science.2990041
发表时间：
1985
期刊：
Science (New York, N.Y.)
影响因子：
--
作者：
Sodroski,J;Patarca,R;Rosen,C;Wong-Staal,F;Haseltine,W
通讯作者：
Haseltine,W